Tilray is a drug manufacturers-specialty & generic business based in Canada. Tilray stocks (APHA.TO) are listed on the TO and all prices are listed in Canadian Dollars. Tilray employs 1,200 staff and has a trailing 12-month revenue of around C$611.1 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||C$N/A|
|52-week range||C$5.64 - C$30.7|
|50-day moving average||C$21.7961|
|200-day moving average||C$19.2083|
|Wall St. target price||C$18.54|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||C$0.116|
Note: The dollar amounts in the table below are in Canadian dollars.
Valuing Tilray stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tilray's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tilray's EBITDA (earnings before interest, taxes, depreciation and amortisation) is CADC$9 million.
The EBITDA is a measure of a Tilray's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||CADC$611.1 million|
|Gross profit TTM||CADC$191 million|
|Return on assets TTM||-1.31%|
|Return on equity TTM||-34.14%|
|Market capitalisation||CADC$4.4 billion|
TTM: trailing 12 months
There are currently 12.0 million Tilray stocks held short by investors – that's known as Tilray's "short interest". This figure is 41.7% up from 8.4 million last month.
There are a few different ways that this level of interest in shorting Tilray stocks can be evaluated.
Tilray's "short interest ratio" (SIR) is the quantity of Tilray stocks currently shorted divided by the average quantity of Tilray stocks traded daily (recently around 3.4 million). Tilray's SIR currently stands at 3.52. In other words for every 100,000 Tilray stocks traded daily on the market, roughly 3520 stocks are currently held short.
However Tilray's short interest can also be evaluated against the total number of Tilray stocks, or, against the total number of tradable Tilray stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tilray's short interest could be expressed as 0.05% of the outstanding stocks (for every 100,000 Tilray stocks in existence, roughly 50 stocks are currently held short) or 0% of the tradable stocks (for every 100,000 tradable Tilray stocks, roughly 0 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Tilray.
Find out more about how you can short Tilray stock.
We're not expecting Tilray to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Tilray stocks were split on a 1:10 basis on 8 December 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tilray stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for Tilray stocks which in turn could have impacted Tilray's stock price.
Over the last 12 months, Tilray's stocks have ranged in value from as little as C$5.64 up to C$30.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (TO average) beta is 1, while Tilray's is 2.6198. This would suggest that Tilray's stocks are significantly more volatile than the average for this exchange and represent a higher risk.
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Everything we know about the GameStop IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Steps to owning and managing China Evergrande Group shares from Canada.
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.